Clinical Reasoning: Therapeutic considerations in myasthenic crisis due to COVID-19 infection

Neurology. 2020 Nov 3;95(18):840-843. doi: 10.1212/WNL.0000000000010651. Epub 2020 Aug 14.

Authors

Phuong Hoang¹, Brigitte Hurtubise², Srikanth Muppidi²

Affiliations

¹ From the Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, CA. pthoang@stanford.edu.
² From the Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, CA.

PMID: 32817186
DOI: 10.1212/WNL.0000000000010651

No abstract available

Publication types

Case Reports

MeSH terms

Betacoronavirus / pathogenicity*
COVID-19
Coronavirus Infections / complications*
Coronavirus Infections / therapy*
Female
Humans
Middle Aged
Myasthenia Gravis / complications*
Myasthenia Gravis / drug therapy
Myasthenia Gravis / therapy*
Pandemics
Pneumonia, Viral / complications*
Pneumonia, Viral / therapy*
SARS-CoV-2